The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) hit a new 52-week high and has $63.80 target or 49.00% above today’s $42.82 share price. The 9 months bullish chart indicates low risk for the $1.49B company. The 1-year high was reported on Nov, 17 by Barchart.com. If the $63.80 price target is reached, the company will be worth $730.10M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 77,748 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 174.26% since April 15, 2016 and is uptrending. It has outperformed by 169.63% the S&P500.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage
Out of 10 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 10 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 20 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, September 15. Cantor Fitzgerald maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) rating on Thursday, September 17. Cantor Fitzgerald has “Buy” rating and $40 price target. The firm has “Strong Buy” rating given on Wednesday, September 14 by Raymond James. Cantor Fitzgerald reinitiated the shares of AERI in a report on Friday, June 3 with “Buy” rating. Needham maintained it with “Buy” rating and $52 target price in Thursday, September 15 report. The firm earned “Buy” rating on Tuesday, November 1 by Aegis Capital. The rating was maintained by RBC Capital Markets on Friday, October 28 with “Outperform”. H.C. Wainwright initiated the stock with “Buy” rating in Tuesday, September 20 report. JMP Securities initiated the shares of AERI in a report on Wednesday, September 9 with “Market Outperform” rating. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, September 17.
According to Zacks Investment Research, “Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s lead Dual- Action product and Triple-Action products are under developmental stages. Aerie Pharmaceuticals, Inc. is headquartered in Bedminster, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.67 in 2016 Q2. Its up 0.28, from 1.39 in 2016Q1. The ratio is positive, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
The Texas-based Teacher Retirement Of Texas has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Grp Incorporated holds 0% or 13,864 shares in its portfolio. Fred Alger Mngmt Incorporated accumulated 80,400 shares or 0.01% of the stock. Cam Gp Hldg A S reported 192,006 shares or 0.06% of all its holdings. Vanguard Gp accumulated 1.01M shares or 0% of the stock. Northern owns 330,379 shares or 0% of their US portfolio. Partner Management Limited Partnership holds 1.28% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 44,345 shares. Bailard reported 113,000 shares or 0.24% of all its holdings. Parametric Port Assocs Ltd Limited Liability Company has invested 0% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Proshare Advsr Ltd Limited Liability Company holds 22,695 shares or 0.01% of its portfolio. Royal Comml Bank Of Canada has 0% invested in the company for 99,451 shares. Manchester Capital Management Limited Liability Co owns 150 shares or 0% of their US portfolio. Wall Street Associates has invested 0.14% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Teachers Retirement Sys Of The State Of Kentucky last reported 0.01% of its portfolio in the stock. Jpmorgan Chase accumulated 284 shares or 0% of the stock.
Insider Transactions: Since July 22, 2016, the stock had 1 insider buy, and 0 sales for $4.38 million net activity. 250,000 shares were bought by Foresite Capital Management II – LLC, worth $4.38 million on Friday, July 22.
Another recent and important Aerie Pharmaceuticals Inc (NASDAQ:AERI) news was published by Investorplace.com which published an article titled: “3 Stocks to Watch Thursday: Viacom, Inc. (VIAB), Aerie Pharmaceuticals Inc …” on September 15, 2016.
AERI Company Profile
Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.